Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
Butalbital / Acetaminophen / Caffeine (1) ·
Butalbital / Aspirin / Caffeine (1) ·
Celecoxib (1) ·
Cetirizine (1) ·
Codeine / Acetaminophen (1) ·
Cyproheptadine (hydrochloride) (1) ·
Dexmethylphenidate (1) ·
Fexofenadine (1) ·
Glimepiride (1) ·
Insulin detemir (1) ·
Insulin glargine (1) ·
Levocetirizine (1) ·
Loperamide (1) ·
Naproxen (sodium; free acid) (1) ·
Pseudoephedrine (hydrochloride; sulfate) (1) ·
Sildenafil (1) ·
Tizanidine (1) ·
Tramadol / Acetaminophen (1)
Aleve (OTC), Naprosyn (Rx), Anaprox (Rx), Naprelan (ER), EC-Naprosyn (enteric-coated), Vimovo (with esomeprazole) (1) ·
Allegra, Allegra Allergy 24 Hour, Mucinex Allergy (combo) — all now OTC in US (1) ·
Amaryl (1) ·
Celebrex (oral capsules), Elyxyb (oral solution, for acute migraine) (1) ·
Fioricet, Esgic; with codeine as Fioricet with Codeine (Schedule III) (1) ·
Fiorinal; with codeine as Fiorinal with Codeine (Schedule III) (1) ·
Focalin, Focalin XR (1) ·
Imodium, Imodium A-D (1) ·
Lantus, Basaglar, Semglee, Toujeo (U-300) (1) ·
Levemir, Levemir FlexTouch (US discontinuation announced 2024) (1) ·
Periactin (US brand discontinued; generic widely available) (1) ·
Sudafed (IR, 12-hour, 24-hour); many combination products including Claritin-D, Allegra-D, Zyrtec-D, Mucinex-D (1) ·
Tylenol with Codeine #3 (30 mg codeine), Tylenol #4 (60 mg codeine), Capital with Codeine, Phenaphen with Codeine (1) ·
Ultracet, Tramacet (1) ·
Viagra, Revatio (1) ·
Xyzal, Xyzal Allergy 24HR (OTC) (1) ·
Zanaflex (1) ·
Zyrtec, Zyrtec-D (1)
None (1) ·
CNS stimulant (1) ·
gut-restricted)]] (1) ·
NDRI (1) ·
PDE5 Inhibitor (1) ·
Psychostimulant (1) ·
selective COX-2)]] (1) ·
weak)]] (1) ·
[[:Category:Alpha-2 adrenergic agonists|Alpha-2 adrenergic agonist]] (1) ·
[[:Category:Analgesics|Analgesic]] (2) ·
[[:Category:Antidiarrheals|Antidiarrheal]] (1) ·
[[:Category:Antihistamines|Antihistamine]] (3) ·
[[:Category:Antihistamines|First-generation antihistamine]] (1) ·
[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (1) ·
[[:Category:Antipyretics|Antipyretic]] (1) ·
[[:Category:Antispastics|Antispastic]] (1) ·
[[:Category:Barbiturates|Barbiturate (butalbital)]] (2) ·
[[:Category:Basal_insulins|Basal insulin]] (2) ·
[[:Category:Decongestants|Decongestant]] (1) ·
[[:Category:Fixed-dose_combinations|Fixed-dose combination]] (3) ·
[[:Category:H1_receptor_antagonists|Histamine H1 receptor antagonist (second-generation)]] (3) ·
[[:Category:Insulins|Insulin]] (2) ·
[[:Category:Insulin_secretagogues|Insulin secretagogue]] (1) ·
[[:Category:Long-acting_insulins|Long-acting insulin analog]] (2) ·
[[:Category:Methylxanthines|Methylxanthine (caffeine)]] (2) ·
[[:Category:Non-opioid_analgesics|Non-opioid analgesic (acetaminophen)]] (2) ·
[[:Category:NSAIDs|Non-steroidal anti-inflammatory (NSAID (1) ·
[[:Category:NSAIDs|Non-steroidal anti-inflammatory (NSAID)]] (1) ·
[[:Category:NSAIDs|NSAID (aspirin)]] (1) ·
[[:Category:Opioid_analgesics|Opioid analgesic (codeine (1) ·
[[:Category:Opioid_receptor_agonists|Peripheral opioid receptor agonist (μ-selective (1) ·
[[:Category:Orexigenics|Appetite-promoting medicine (orexigenic)]] (1) ·
[[:Category:Schedule_III_controlled_substances|Schedule III controlled substance]] (2) ·
[[:Category:Serotonin antagonists|Serotonin 5-HT2 antagonist]] (1) ·
[[:Category:Skeletal muscle relaxants|Skeletal muscle relaxant (centrally-acting)]] (1) ·
[[:Category:Sulfonylureas|Sulfonylurea (third-generation)]] (1) ·
[[:Category:Sympathomimetics|Sympathomimetic (indirect-acting)]] (1)
None (10) ·
Norepinephrine–dopamine reuptake inhibition (DAT, NET), d-threo enantiomer of methylphenidate (1) ·
Selective inhibitor of phosphodiesterase type 5 (PDE5), preventing cGMP breakdown in vascular smooth muscle. In the corpus cavernosum, potentiates the NO/cGMP cascade triggered by sexual stimulation. (1) ·
'"`UNIQ--vote-00000017-QINU`"' Anticholinergic and sedating, with the standard first-generation antihistamine Beers-list concerns in elderly patients'"`UNIQ--ref-00000018-QINU`"'. (1) ·
'"`UNIQ--vote-00000237-QINU`"' Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio; provides basal hepatic glucose suppression and peripheral glucose uptake without prandial peaks'"`UNIQ--ref-00000238-QINU`"'. (1) ·
'"`UNIQ--vote-00000391-QINU`"' Minimal CYP metabolism; mostly renally cleared unchanged. Cetirizine is the active racemate; levocetirizine is the active R-enantiomer marketed separately'"`UNIQ--ref-00000392-QINU`"'. (1) ·
'"`UNIQ--vote-00000950-QINU`"' Mostly renally cleared unchanged; dose-reduce in renal impairment. Like cetirizine, retains slightly more sedation than fexofenadine in some users'"`UNIQ--ref-00000951-QINU`"'. (1) ·
'"`UNIQ--vote-00000CC9-QINU`"' Mostly excreted unchanged in feces and urine; P-glycoprotein substrate (the basis of the fruit-juice interaction). (1) ·
'"`UNIQ--vote-00001513-QINU`"' The combination with acetaminophen provides additive non-opioid analgesia and lowers required codeine dose. CYP2D6 PGx is one of the most clinically actionable in current pharmacology; CPIC supports genotype-guided opioid selection'"`UNIQ--ref-00001514-QINU`"'. (1)
'"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"' (1) ·
'"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"' (1) ·
'"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"' (1) ·
'"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"', '"`UNIQ--vote-00000026-QINU`"', '"`UNIQ--vote-00000027-QINU`"', '"`UNIQ--vote-00000028-QINU`"' (2) ·
'"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"' (1) ·
'"`UNIQ--vote-00000239-QINU`"', '"`UNIQ--vote-0000023A-QINU`"' (1) ·
'"`UNIQ--vote-00000393-QINU`"', '"`UNIQ--vote-00000394-QINU`"', '"`UNIQ--vote-00000395-QINU`"' (1) ·
'"`UNIQ--vote-00000491-QINU`"' (1) ·
'"`UNIQ--vote-00000705-QINU`"', '"`UNIQ--vote-00000706-QINU`"' (1) ·
'"`UNIQ--vote-00000952-QINU`"', '"`UNIQ--vote-00000953-QINU`"' (1) ·
'"`UNIQ--vote-00000CCA-QINU`"', '"`UNIQ--vote-00000CCB-QINU`"' (1) ·
'"`UNIQ--vote-00000FCF-QINU`"', '"`UNIQ--vote-00000FD0-QINU`"', '"`UNIQ--vote-00000FD1-QINU`"' (1) ·
'"`UNIQ--vote-00001372-QINU`"', '"`UNIQ--vote-00001373-QINU`"' (1) ·
'"`UNIQ--vote-00001515-QINU`"', '"`UNIQ--vote-00001516-QINU`"' (1) ·
'"`UNIQ--vote-0000152F-QINU`"' (1) ·
'"`UNIQ--vote-0000159D-QINU`"', '"`UNIQ--vote-0000159E-QINU`"' (1) ·
'"`UNIQ--vote-000015B6-QINU`"' (1)
None (1) ·
1-2 capsules (50 mg butalbital / 325 mg acetaminophen / 40 mg caffeine each) PO every 4 hours as needed; maximum 6 capsules/d (1) ·
1-2 capsules (50 mg butalbital / 325 mg aspirin / 40 mg caffeine each) PO every 4 hours as needed; maximum 6 capsules/d (1) ·
1-2 mg PO once daily with breakfast; titrate by glycemic response (1) ·
1-2 tablets (15-60 mg codeine, 300-600 mg acetaminophen) PO every 4-6 hours as needed (1) ·
10 mg PO once daily (5 mg in older adults or if sedation occurs) (1) ·
2 mg PO every 6-8 hours; titrate by 2-4 mg per dose every 1-4 days; maximum single dose 16 mg, maximum daily dose 36 mg (1) ·
2 tablets (75 mg tramadol / 650 mg acetaminophen) PO every 4-6 hours as needed; maximum 8 tablets/day for ≤5 days (1) ·
4 mg PO initially, then 2 mg after each loose stool, '''not to exceed 16 mg/d''' (8 mg OTC); chronic-use lower (1) ·
5 mg PO once daily in the evening (1) ·
50 mg ~1 h before sexual activity (ED); 20 mg TID (PAH) (1) ·
60 mg PO BID or 180 mg PO once daily (1) ·
Allergy: 4 mg PO TID. Serotonin syndrome: 12 mg loading dose PO or by nasogastric tube, then 2 mg every 2 hours until clinical improvement. Appetite stimulation: 2-4 mg PO TID-QID (1) ·
IR: 60 mg PO every 4-6 hours. 12-hour ER: 120 mg PO every 12 hours. 24-hour ER: 240 mg PO once daily. Pediatric: weight-based (1) ·
Osteoarthritis: 200 mg PO once daily or 100 mg BID. Rheumatoid arthritis: 100-200 mg PO BID. Acute pain: 400 mg loading, then 200 mg every 12 hours (1) ·
OTC: 220 mg PO every 8-12 hours, max 660 mg/24h. Rx: 250-500 mg PO BID. Acute gout: 750 mg loading then 250 mg every 8 hours (1) ·
~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose (1) ·
~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose. Frequently dosed BID at moderate-to-high doses (1)
None (1) ·
1 mg, 2 mg, 4 mg tablets (1) ·
100 U/mL (Lantus, Basaglar, Semglee) vials and pens; 300 U/mL (Toujeo) pens (1) ·
100 U/mL FlexTouch pen, vial (1) ·
2 mg capsules and tablets; 1 mg/5 mL oral solution; combined with simethicone (Imodium Multi-Symptom) (1) ·
25, 50, 100 mg tabs (Viagra); 20 mg tabs and 10 mg/mL oral suspension (Revatio) (1) ·
30, 60, 180 mg tablets; 30 mg ODT; 6 mg/mL oral suspension; all OTC (1) ·
5 mg tablets; 2.5 mg/5 mL oral solution; OTC (1) ·
5 mg, 10 mg tablets; 5 mg, 10 mg chewables; 1 mg/mL oral syrup; OTC (1) ·
50/325/40 mg capsules (1) ·
50/325/40 mg capsules and tablets; oral solution (1) ·
Capsules 50, 100, 200, 400 mg; Elyxyb oral solution 25 mg/mL (1) ·
Codeine/acetaminophen 15/300 (#2 historical), 30/300 (#3), 60/300 (#4) mg tablets; 12/120 mg/5 mL elixir (1) ·
IR tablets 30, 60 mg; 12-hour ER tablets 120 mg; 24-hour ER tablets 240 mg; oral liquid; multiple combination products with antihistamines, NSAIDs, or expectorants (1) ·
OTC tablets 220 mg; Rx tablets 250, 375, 500 mg; ER tablets 375, 500, 750 mg (Naprelan); oral suspension 125 mg/5 mL; enteric-coated tablets (EC-Naprosyn) (1) ·
Tablets 2, 4 mg; capsules 2, 4, 6 mg ('''capsules and tablets are not bioequivalent''': capsules slower with food; tablets faster on empty stomach) (1) ·
Tablets 4 mg; oral syrup 2 mg/5 mL (1) ·
Tramadol/acetaminophen 37.5/325 mg tablets (1)
None (1) ·
10 mg/d (adults) (1) ·
100 mg/d (ED); 20 mg TID (PAH) (1) ·
1500 mg/day (Rx); 660 mg/24h (OTC, without provider direction) (1) ·
16 mg/d (8 mg/d OTC) (1) ·
180 mg/d (adults) (1) ·
240 mg/day (1) ·
32 mg/day adult; weight-based pediatric ceiling (1) ·
36 mg/day in three divided doses; single dose maximum 16 mg (1) ·
400 mg/day for chronic indications; higher for short-term acute pain (1) ·
5 mg/d (adults) (1) ·
6 capsules/d (300 mg butalbital, 1950 mg acetaminophen, 240 mg caffeine) (1) ·
6 capsules/d (300 mg butalbital, 1950 mg aspirin, 240 mg caffeine) (1) ·
8 mg/d (1) ·
8 tablets/d (300 mg tramadol / 2600 mg acetaminophen); 5-day duration limit per label (1) ·
Acetaminophen 4 g/d absolute; codeine 240-360 mg/d typical practical limit (1) ·
Titrated to glucose (1) ·
Titrated to glucose; no fixed ceiling (1)
12-24 hours (2) ·
24 hours (3) ·
3-6 hours per dose (1) ·
4-6 hours (4) ·
4-6 hours (IR); 12-24 hours (ER) (1) ·
6-8 hours (1) ·
8-12 hours (1) ·
8-12 hours (the long-duration feature relative to ibuprofen) (1) ·
IR 4–6 h; XR 8–12 h (1) ·
~12-24 hours (dose-dependent; BID dosing often needed at higher doses) (1) ·
~24 hours per dose (peakless profile by design) (1) ·
~4 h (1)
12-17 hours'"`UNIQ--ref-00000029-QINU`"' (1) ·
2.2 h (IR parent); ~3 h (XR parent) (1) ·
2.5 hours (short, requires TID-QID dosing)'"`UNIQ--ref-0000001D-QINU`"' (1) ·
8-10 hours (longer in elderly and renal impairment)'"`UNIQ--ref-00000396-QINU`"' (1) ·
8-16 hours'"`UNIQ--ref-0000001E-QINU`"' (1) ·
9-16 hours (pH-dependent: acidic urine shortens, alkaline urine substantially extends)'"`UNIQ--ref-0000001B-QINU`"' (1) ·
Butalbital ~35 hours (long; cumulative effects with frequent use); acetaminophen 1-3 hours; caffeine 3-7 hours'"`UNIQ--ref-0000159F-QINU`"' (1) ·
Butalbital ~35 hours; aspirin (acetyl group) ~15 minutes, salicylate 2-3 hours; caffeine 3-7 hours'"`UNIQ--ref-000015B7-QINU`"' (1) ·
Codeine 2.5-3.5 hours; acetaminophen 1-3 hours'"`UNIQ--ref-00001517-QINU`"' (1) ·
Tramadol ~5-7 hours (M1 metabolite ~9 hours); acetaminophen 1-3 hours'"`UNIQ--ref-00001530-QINU`"' (1) ·
~11 hours'"`UNIQ--ref-00000029-QINU`"' (1) ·
~12 hours apparent (functional duration ~24 hours due to depot release kinetics)'"`UNIQ--ref-0000023B-QINU`"' (1) ·
~14 hours'"`UNIQ--ref-00000CCC-QINU`"' (1) ·
~4 h (1) ·
~5-9 hours (parent and active metabolites combined)'"`UNIQ--ref-00000492-QINU`"' (1) ·
~7 hours apparent'"`UNIQ--ref-00001374-QINU`"' (1) ·
~8 hours (longer in elderly and renal impairment)'"`UNIQ--ref-00000954-QINU`"' (1) ·
~9-14 hours'"`UNIQ--ref-00000FD2-QINU`"' (1)
Butalbital well-absorbed; aspirin 50-75%; caffeine ~100%'"`UNIQ--ref-000015B8-QINU`"' (1) ·
Butalbital well-absorbed; caffeine ~100%; acetaminophen 85-98%'"`UNIQ--ref-000015A0-QINU`"' (1) ·
Codeine ~60% (oral); acetaminophen 85-98%'"`UNIQ--ref-00001518-QINU`"' (1) ·
High (oral); not significantly affected by food'"`UNIQ--ref-00000397-QINU`"' (1) ·
Tramadol ~75% (oral); acetaminophen 85-98%'"`UNIQ--ref-00001531-QINU`"' (1) ·
~0.3% (oral; extensive first-pass via CYP3A4 and P-glycoprotein-mediated efflux at the intestinal and blood-brain barriers limit systemic and CNS exposure at therapeutic doses)'"`UNIQ--ref-00000FD3-QINU`"' (1) ·
~100% (oral; not significantly affected by food)'"`UNIQ--ref-00000493-QINU`"' (1) ·
~100% from subcutaneous depot (by definition of the route) (1) ·
~22–25% (1) ·
~33% (oral; fruit juices including grapefruit, orange, and apple reduce absorption substantially via OATP1A2 inhibition — distinctive interaction not seen with most other H1s)'"`UNIQ--ref-00000CCD-QINU`"' (1) ·
~40% (1) ·
~40% (oral); food and formulation substantially alter the absorption profile'"`UNIQ--ref-0000001E-QINU`"' (1) ·
~60% from subcutaneous depot (reduced by reversible albumin binding via the myristic acid side chain that also extends duration)'"`UNIQ--ref-00001375-QINU`"' (1) ·
~85-90% (oral; not significantly affected by food)'"`UNIQ--ref-00000955-QINU`"' (1) ·
~90% (oral, low first-pass)'"`UNIQ--ref-0000001C-QINU`"' (1) ·
~95% (oral)'"`UNIQ--ref-0000001F-QINU`"' (1) ·
~95% (oral)'"`UNIQ--ref-0000002A-QINU`"' (1) ·
~99% (oral)'"`UNIQ--ref-0000002A-QINU`"' (1)
None (1) ·
Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning (fetal renal dysfunction, oligohydramnios); contraindicated from 30 weeks (risk of premature ductus arteriosus closure)'"`UNIQ--ref-0000002B-QINU`"' (2) ·
Avoid; neonatal opioid withdrawal documented.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Avoid; switch to insulin. Neonatal hypoglycemia reported.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Avoided; barbiturate + aspirin teratogenicity and bleeding concerns.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Category B (1) ·
Category C (1) ·
Generally avoided; barbiturate exposure in late pregnancy can produce neonatal withdrawal and respiratory depression.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered acceptable when needed.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; loratadine and cetirizine have more pregnancy data and are typically preferred.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; widely used. Cetirizine and loratadine remain the more-studied alternatives.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; widely used. Levocetirizine (the R-enantiomer) is an alternative with similar safety.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Insulin is the preferred glucose-lowering therapy in pregnancy; glargine has reassuring observational data, though NPH and detemir remain the traditional choices.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; older agent with substantial use experience.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
One of the better-studied basal insulin analogs in pregnancy; reassuring data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Some controversial signal for first-trimester gastroschisis association in observational studies; limited use is generally considered acceptable after the first trimester.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
None (1) ·
'''[[USLegal:Behind-the-counter|Behind-the-counter]] in US''' under the Combat Methamphetamine Epidemic Act 2005: purchase restricted to ≤3.6 g/day and ≤9 g/30 days, with photo ID, logbook signature, and quantity logging required. Several states schedule higher than federal (1) ·
OTC in US (4) ·
Rx-only in US (1) ·
Schedule II (1) ·
[[USLegal:Over-the-counter|OTC]] in US at ≤220 mg/tablet and ≤660 mg/day; [[USLegal:Prescription only|Rx-only]] at higher strengths (1) ·
[[USLegal:Prescription only|Rx-only]] in US (5) ·
[[USLegal:Prescription only|Rx-only]] in US. Not a controlled substance, distinguishing it from carisoprodol among muscle-spasm options'"`UNIQ--ref-0000001F-QINU`"' (1) ·
[[USLegal:Schedule III|Schedule III controlled substance]] in US (Fiorinal is scheduled federally; Fioricet with acetaminophen is unscheduled federally despite identical butalbital content, a regulatory quirk) (1) ·
[[USLegal:Schedule III|Schedule III controlled substance]] in US. '''Contraindicated in children <12''' for any indication and in any age post-tonsillectomy/adenoidectomy (FDA 2017 black-box advisory)'"`UNIQ--ref-00001519-QINU`"' (1) ·
[[USLegal:Schedule IV|Schedule IV controlled substance]] in US (tramadol was reclassified from non-controlled to Schedule IV in 2014 after recognition of dependence risk) (1)
Showing below up to 18 results in range #1 to #18.


